- PMGC Holdings said Friday that its unit, NorthStrive Biosciences, amended a deal with MOA Life Plus to run human trials for EL-22 and EL-32, targeting muscle and lean mass preservation.
- Iterum Therapeutics announced on Friday that it had filed a winding-up petition in Ireland, which is set to be heard on April 13, 2026.
- Lantern Pharma said the FDA cleared its Investigational New Drug application for STAR-001, a targeted therapy for relapsed or refractory CNS cancers.
U.S. equities were in the green in Monday’s pre-market trade amid the ongoing tensions in the Middle East, with President Donald Trump stating on Sunday that Iran had agreed to the 15-point ceasefire plan “for the most part.”
At the time of writing, the SPDR S&P 500 ETF (SPY), which tracks the S&P 500 index, was up 0.49%; the Invesco QQQ Trust ETF (QQQ) rose 0.42%; and the SPDR Dow Jones Industrial Average ETF Trust (DIA) gained 0.47%. Retail sentiment on Stocktwits regarding the S&P 500 ETF was in the ‘extremely bearish’ territory.
Here are the top stocks making the biggest moves in Monday’s pre-market trade:
PMGC Holdings shares soared more than 66% in Monday’s pre-market session. The company announced on Friday that its wholly-owned subsidiary, NorthStrive Biosciences, has amended its existing agreement with MOA Life Plus for human clinical trials of its lead candidate EL-22, as well as EL-32, to study the preservation of muscle and lean mass.
ELAB stock is down 95% year-to-date.
Iterum Therapeutics PLC (ITRM)
Iterum Therapeutics shares more than doubled to soar 110% in Monday’s pre-market trade. The company announced on Friday that it had filed a winding-up petition in Ireland, which is set to be heard on April 13, 2026.
ITRM stock is down 90% year-to-date.
Lantern Pharma shares gained more than 17% in Monday’s pre-market session. The company announced on Friday that its CEO Panna Sharma continues to serve the Dallas-based biopharmaceutical company. It also announced that the U.S. Food and Drug administration (FDA) cleared its Investigational New Drug (IND) application for STAR-001, its treatment for patients with relapsed or refractory central nervous system (CNS) malignancies.
LTRN stock is down 63% year-to-date.
Also See: BUR Stock Sinks 40% Following A Reported US Appeals Court Ruling — What Is The Argentina Connection?
For updates and corrections, email newsroom[at]stocktwits[dot]com.